Kamada Ltd. (KMDA) News
Follow Kamada Ltd. (KMDA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Kamada Reports Record Nine-Month Results, Raises 2026 Guidance
Kamada reported nine-month revenue of $152.2 million, up 12% year over year, and adjusted EBITDA of $40.9 million. It raised 2026 revenue guidance to $205 million–$208 million and adjusted EBITDA guidance to $52 million–
EQUITY | Nov 09, 2026, 03:32 PM UTC
M
Kamada Q3 Revenue Rises 11%, Company Raises Forecast
EQUITY | Nov 09, 2026, 12:13 PM UTC
H
Weekly Recap: 2026 guidance $200—$205M rev and 2025 projections, SHIELD 2028
Kamada Ltd (NASDAQ:KMDA) reaffirmed 2026 targets of $200—$205M revenue and $50—$53M EBITDA after H1 delivered roughly $100M revenue, $26M EBITDA and ~$18M operating cash flow, while guiding 2025 revenue from GLASSIA roya
EARNINGS | Sep 28, 2026, 11:03 AM UTC
L
KMDA - CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand
KMDA - CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand
NEWS | Sep 17, 2026, 11:00 AM UTC
H
Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious co
GEOPOLITICS | Sep 10, 2026, 11:01 AM UTC
L
KMDA - Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
KMDA - Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 10, 2026, 11:01 AM UTC
L
KMDA - Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
KMDA - Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
EQUITY | Sep 03, 2026, 08:03 PM UTC
M
Kamada declares $0.17 cash dividend amid first-half 2026 record revenue and profitability
Kamada (KMDA) declares a cash dividend of $0.17 per share and reports record-high revenue and profitability for the first six months of 2026.
EQUITY | Aug 17, 2026, 11:00 AM UTC
L
Kamada Posts Record Q2 Revenue
Kamada reports record Q2 revenue of $54.9M, up 23% YoY, and Adjusted EBITDA of $14.1M, up 29% YoY
EARNINGS | Aug 12, 2026, 11:27 AM UTC
L
Kamada Affirms FY2026 Sales Guidance
Kamada affirms FY2026 sales outlook of $200-205 million
EARNINGS | Aug 12, 2026, 11:07 AM UTC
L
KMDA Reports Record-High Q2 and H1 2026 Results
KMDA reports record-high Q2 and H1 2026 financial results with double-digit growth
EARNINGS | Aug 12, 2026, 11:05 AM UTC
L
KMDA Announces CFO Transition
Kamada announces planned transition of Chief Financial Officer
MNA | Aug 12, 2026, 11:00 AM UTC
L
KMDA - Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
KMDA - Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
EARNINGS | Aug 05, 2026, 11:00 AM UTC
L
KMDA +3% in pre-mkt following earlier PR: Kamada Announces a Three-Year $50M Sales Agreement to Supply Plasma to a Leading Biopharmaceutical
KMDA +3% in pre-mkt following earlier PR: Kamada Announces a Three-Year $50M Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies Through Texas Centers, Commercial S
EQUITY | Jul 20, 2026, 01:17 PM UTC